Washington State Medical Oncology Society (WSMOS)
Virtual Fall Conference Series October 29, 2020 & November 5, 2020
WSMOS Virtual Fall Conference Series October 29, & November 5, 2020
October 29, 2020
|6pm – 8pm|
Petros Grivas, MD, PhD will focus on the impact of COVID on cancer patients, using insights from the CCC19 consortium registry he has been leading.
Lawrence Corey, MD principal investigator of the Fred Hutch-based operations center of the COVID-19 Prevention Network (CoVPN) will provide an update on COVID-19 vaccine research.
Matthew Sturm, ECG Management Consultants - will speak on the impact of COVID on healthcare, particularly cancer care, including the financial and operational changes it has brought and how cancer programs are responding.
November 5, 2020
|6pm – 8pm|
Join us for a discussion on the national and state legislative landscape following the November 3rd election, including the financial impact on hospitals and opportunities to be politically active. Andrew McKechnie of Peck Madigan Jones will discuss the election's impact on cancer care on a national level, and Kathryn Kolan, WSMOS Lobbyist, will provide a state level update.
We would like to encourage all of our Hematology and Oncology colleagues in the state of Washington, including Physicians, Fellows, Emeritus, Office Managers, Administrators, Pharmacists, NP’s, PA’s, and RN’s to have your voices heard. With your support, WSMOS will continue to be the leading professional organization for oncologists in the state of Washington and a resource for the oncology community through professional education, and information dissemination.
Membership is critical to the continued advancement of WSMOS interests:
- To identify and work to improve oncology practice issues that adversely affect patient access to cancer care.
- To act as a patient advocate to assure that patients have access to the best available care.
- To support and encourage clinical research against cancer. To learn more about joining the WSMOS please contact firstname.lastname@example.org.
Speakers - October 29, 2020
Petros Grivas, MD, PhD
In response to the pandemic caused by SARS-CoV-2, the COVID-19 and Cancer Consortium was formed on March 15th, 2020. Two days later, we launched a registry to collect detailed clinical information on patients with cancer and either presumed or lab-proven COVID-19 infection. This consortium has grown rapidly to about 124 United States, Canadian and Spanish institutions, and also internationally, including collaboration with the European Society of Medical Oncology. We have now >4,100 cases and we published our initial reports at Lancet and Cancer Discovery. We believe this to be the largest such cohort assembled to date and have findings that can immediately help inform discussions. Specifically, we report data on outcomes across cancer types considering several clinical factors and therapies.We independently confirm previously reported risk factors for COVID-19 severity in the general population, specifically for the cancer population, which raises concerns in this population. In addition, there are important cancer-specific risk factors that are associated with increased 30-day mortality, such as progressive cancer status. This may trigger immediate clinical considerations and support further studies in the COVID-19 era. Although our follow-up period is short, given the timeliness of this information, this can generate great discussion and exchange.
Lawrence Corey, MD
Past President and Director, Fred Hutchinson Cancer Research Center Professor, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center Professor, Medicine and Laboratory Medicine, University of Washington
Dr. Larry Corey is an internationally renowned expert in virology, immunology and vaccine development, and the former president and director of the Fred Hutchinson Cancer Research Center. His research focuses on herpes viruses, HIV, the novel coronavirus and other viral infections, including those associated with cancer. He is principal investigator of the HIV Vaccine Trials Network, or HVTN, which conducts studies of HIV vaccines at over 80 clinical trials sites in 16 countries on five continents. Under his leadership, the HVTN has become the model for global, collaborative research. Dr. Corey is also the principal investigator of the Fred Hutch-based operations center of the COVID-19 Prevention Network (CoVPN) and co-leads the Network’s COVID-19 vaccine testing pipeline. The CoVPN is carrying out the large Operation Warp Speed portfolio of COVID-19 vaccines and monoclonal antibodies intended to protect people from COVID-19.Dr. Corey is a member of the US National Academy of Medicine and the American Academy of Arts and Sciences and was the recipient of the Parran Award for his work in HSV-2, the American Society of Microbiology Cubist Award for his work on antivirals, and the University of Michigan Medical School Distinguished Alumnus Award. He is one of the most highly cited biomedical researchers in the last 20 years and is the author, coauthor or editor of over 1000 scientific publications.
Matt Sturm is a Principal at ECG Management Consultants, where he leads the firm’s Oncology Services Practice. For the last 17 years Matt has assisted clients with developing and expanding their oncology programs through improved clinical coordination, enhanced physician leadership, and increased clinical capabilities. Matt has completed over 130 oncology-related engagements with over 70 clients. In addition to Matt’s leadership of ECG’s Oncology practice, he holds leadership roles with ACE and the ACCC. Matt is also a frequent author and speaker on related topics and is coauthor and editor of the book Oncology: Strategies for Superior Service Line Performance.Matt will describe industry best practices from across the country to support the successful management cancer program operations in the COVID-19 environment. He will also provide practical guidance based on lessons learned from leading institutions, addressing how to position operations to meet the anticipated surge in patient volumes while also continuing to ensure the safety of patients and staff at the center. Matt will introduce strategies to optimize performance in a COVID-19 environment and explore strategies to transition patients and staff to alternative settings, as needed.
Speakers - November 5, 2020
Named one of The Hill publications “Top Lobbyists” in D.C., Andrew McKechnie brings a wealth of public policy and political experience to Peck Madigan Jones. During his time on Capitol Hill, and as a consultant, Andrew has been a key player for over a decade on many of the major legislative and regulatory efforts impacting the health care sector.
Andrew previously served as policy advisor to Senator Chuck Grassley (R-IA) while he was the Senior Republican on the Senate Finance Committee. Prior to his work with Senator Grassley and the Senate Finance Committee, he served as a Legislative Assistant to former Senator Norm Coleman (R-MN) and former Rep. Jim Ramstad (R-MN), a senior member of the Ways and Means Committee. In addition to his legislative experience on Capitol Hill, Andrew has worked on Presidential, House and Senate campaigns.
With a strong background in health care policy, Andrew is a particularly valuable resource to clients trying to navigate and respond to the highly-regulated health care industry.Andrew lives in D.C. with his wife and two children. In his free time, he is a competitive triathlete, completing four Ironman races.
Katie Kolan, JD
Katie Kolan – a native of NW Washington – led the government affairs and policy team for the Washington State Medical Association for a decade. Katie holds a J.D. from Golden Gate University School of Law. Katie got the lobbying ‘bug’ after working for a state senator and in legislative roles for Columbia Legal Services, a state agency, and in other legal capacities.
She has over a decade of experience in advocacy, coalition building and lobbying, and volunteer work in the community at-large. She’s interest and focus in healthcare and medical ethics issues, P&C insurance law, administrative law, end-of-life care, health insurance and medical business/industry development and technology. When she’s not working, she’s likely working out and also maintains an abiding interest in sci-fi, geeking out on politics and being out in the forest for days.